Please assess the completion status of the following clinical trial:

Trial Title: Instillation of Gemcitabine in Patients With Superficial Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical evidence of superficial transitional cell carcinoma of the bladder~* Males or females at least 18 years of age~* Karnofsky Performance Status greater than or equal to 70%~* Patient compliance and geographic proximity that allow adequate follow-up~* Female patients with reproductive potential must use a reliable contraceptive method if appropriate (for example, intrauterine device \[IUD\], birth control pills, or barrier device) during the study. Female patients with reproductive potential must have a negative serum pregnancy test within 7 days of study enrollment.~* Signed informed consent.~Exclusion Criteria:~* Clinical evidence of muscle-invasive or locally advanced bladder cancer~* Clinical evidence of upper urinary tract tumor~* Distant metastases~* Other malignancies within the last 2 years, except non-melanotic skin tumors, carcinoma in situ of the cervix or organ-confined prostate cancer after curative therapy~* Severe concomitant psychiatric disease~* Febrile, active infection~* Other serious concomitant disorders that would compromise the safety of the patient or his/her ability to complete the study according to the protocol, at the discretion of the investigator (for example, unstable angina pectoris, uncontrolled diabetes mellitus)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).